Skip to main content
Clinical Trials/NL-OMON24865
NL-OMON24865
Recruiting
Not Applicable

A randomized placebo controlled double blind clinical trial comparing selenium and pentoxifylline in patients with mild Graves' orbitopathy.

Prof. dr. W.M. WiersingaDept. of Endocrinology and MetabolismAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamT: +31 20 5666071F: +31 20 6917682e-mail: w.m.wiersinga@amc.uva.nl0 sites156 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Graves' orbitopathy
Sponsor
Prof. dr. W.M. WiersingaDept. of Endocrinology and MetabolismAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamT: +31 20 5666071F: +31 20 6917682e-mail: w.m.wiersinga@amc.uva.nl
Enrollment
156
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Prof. dr. W.M. WiersingaDept. of Endocrinology and MetabolismAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamT: +31 20 5666071F: +31 20 6917682e-mail: w.m.wiersinga@amc.uva.nl

Eligibility Criteria

Inclusion Criteria

  • 1\. Graves' hyperthyroidism, euthyroid for at least two months by antithyroid drugs of surgery (at least 6 months if I131 is used;
  • 2\. Mild Graves' ophthalmopathy (at least 1 sign), with a disease duration of less than 18 months;
  • 3\. No past treatment of the ophthalmopathy except for local measures;
  • 4\. Age 18\-70 years.

Exclusion Criteria

  • 1\. NOSPECS class 2c;
  • 2\. Proptosis \>22 mm;
  • 3\. Diplopia in primary or reading position, and/or ocular torticollis;
  • 4\. Mono\-ocular duction in any direction of less than 20 degrees;
  • 5\. Optic nerve involvement;
  • 6\. Pregnancy, drugs/alcohol abuse, severe concomitant illness, no informed consent, use of selenium or pentoxifylline containing preparations.

Outcomes

Primary Outcomes

Not specified

Similar Trials